FDA approves an unbranded version of megablockbuster Humira, but AbbVie says it won't 'currently' launch
Late last week, the FDA approved an sBLA for unbranded labeling for AbbVie’s megablockbuster Humira (adalimumab), opening the door for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
